The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

Robert L. Stevenson,Daniel Ford,Anjali Zarkar,John Glaholm,Emilio Porfiri,Alice Tew,Ahmed El Modir,Nicholas D. James

The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

2017

Robert L. Stevenson
Daniel Ford
Anjali Zarkar
John Glaholm
Emilio Porfiri
Alice Tew
Ahmed El Modir
Nicholas D. James

e16048 Background: Phase III studies have demonstrated survival benefits from abiraterone1 (Abi), and Enzalutamide2 (MDV3100; Enz) following disease progression in metastatic castrate resistant pro...

Keywords:

Disease
Pathology
Castrate-resistant prostate cancer
Abiraterone
Oncology
Medicine
Enzalutamide
Internal medicine
disease progression
castrate resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations